BNOX
Bionomics Limited
Bionomics Limited (BNOX) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 47.7, with 0/3 trend checks passing.
BNOX with MA50 and MA200
Key levels & signals
BNOX valuation multiples (TTM)
BNOX analyst consensus
Bionomics Limited (BNOX) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.25, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 9.3% and below the 200-day moving average by 54.4%.
BNOX currently has an RSI reading of 47.7, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing BNOX next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Bionomics Limited
Bionomics Limited is an Australian biopharmaceutical company operating at the clinical stage, dedicated to the discovery and advancement of innovative therapeutic compounds. Its research efforts primarily target central nervous system disorders and various cancers, with operations spanning Australia and the United States. A key experimental medicine in its portfolio is BNC210. This compound, which functions as a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, has successfully concluded Phase 2 trials for addressing social anxiety disorder and post-traumatic stress disorder. The company is also developing BNC375, a small molecule therapeutic aimed at improving cognitive function in patients suffering from Alzheimer's disease. Another asset, BNC101, a monoclonal antibody engineered to target cancer stem cells, has concluded its Phase 1 clinical assessment. Moreover, Bionomics is advancing BNC105, a vascular disrupting agent. This agent is currently in Phase 2 clinical trials for the treatment of refractory colorectal cancer and in Phase 1 trials for individuals with relapsed/refractory chronic lymphocytic leukemia. Further bolstering its capabilities, Bionomics Limited maintains a licensing agreement with the pharmaceutical giant Merck & Co., Inc. Established in 1996, the company maintains its corporate headquarters in Eastwood, Australia.
BNOX shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about BNOX
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.